Literature DB >> 22434139

Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells.

Md Nasimuzzaman1, Derek A Persons.   

Abstract

Foamy viruses (FVs) (spumaretroviruses) are good alternative to retroviruses as gene therapy vector. Despite four decades since the discovery of FV, its receptor molecule is still unknown. FV vector transduction of human CD34(+) cells was inhibited by culture with fibronectin. Because fibronectin contains heparin-binding domain, the interactions of fibronectin with heparan sulfate (HS) on cells might be inhibitory to FV transduction. These observations led us to investigate whether HS is a receptor for FV. Two mutant CHO cell lines (but not parental wild type) lacking cell surface HS but not chondroitin sulfate (CS) were largely resistant to FV attachment and transduction. Inhibition of HS expression using enzymes or chemicals greatly reduced FV transduction in human, monkey, and rodent cells. Raji cells, which lack HS and were largely resistant to FV, were rendered more permissive through ectopic expression of syndecan-1, which contains HS. In contrast, mutant syndecan-1-expressing cells were largely resistant to FV. Our findings indicate that cellular HS is a receptor for FV. Identifying FV receptor will enable better understanding of its entry process and optimal use as gene therapy vector to treat inherited and pathogenic diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434139      PMCID: PMC3369305          DOI: 10.1038/mt.2012.41

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

Review 1.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Molecular biology of foamy viruses.

Authors:  Axel Rethwilm
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

3.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

4.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

5.  Identification of amino acid residues important for heparan sulfate proteoglycan interaction within variable region 3 of the feline immunodeficiency virus surface glycoprotein.

Authors:  Qiong-Ying Hu; Elizabeth Fink; Meaghan Happer; John H Elder
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Improved foamy virus vectors with minimal viral sequences.

Authors:  Grant Trobridge; Neil Josephson; George Vassilopoulos; Jaclynn Mac; David W Russell
Journal:  Mol Ther       Date:  2002-09       Impact factor: 11.454

7.  Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles.

Authors:  Kristin Stirnnagel; Daniel Lüftenegger; Annett Stange; Anka Swiersy; Erik Müllers; Juliane Reh; Nicole Stanke; Arend Grosse; Salvatore Chiantia; Heiko Keller; Petra Schwille; Helmut Hanenberg; Hanswalter Zentgraf; Dirk Lindemann
Journal:  Retrovirology       Date:  2010-05-17       Impact factor: 4.602

8.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

9.  Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.

Authors:  Shaun R Opie; Kenneth H Warrington; Mavis Agbandje-McKenna; Sergei Zolotukhin; Nicholas Muzyczka
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin.

Authors:  T P Richardson; V Trinkaus-Randall; M A Nugent
Journal:  J Cell Sci       Date:  2001-05       Impact factor: 5.285

View more
  32 in total

1.  Advances in foamy virus vector technology and disease correction could speed the path to clinical application.

Authors:  Els Verhoeyen
Journal:  Mol Ther       Date:  2012-06       Impact factor: 11.454

2.  Heparan sulfate in baculovirus binding and entry of mammalian cells.

Authors:  Md Nasimuzzaman
Journal:  J Virol       Date:  2014-04       Impact factor: 5.103

3.  Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells.

Authors:  Olivier Humbert; Don W Gisch; Martin E Wohlfahrt; Amie B Adams; Phil D Greenberg; Tom M Schmitt; Grant D Trobridge; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2016-04-08       Impact factor: 11.454

4.  CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Authors:  Thivyan Thayaparan; Roseanna M Petrovic; Daniela Y Achkova; Tomasz Zabinski; David M Davies; Astero Klampatsa; Ana C Parente-Pereira; Lynsey M Whilding; Sjoukje Jc van der Stegen; Natalie Woodman; Michael Sheaff; Jennifer R Cochran; James F Spicer; John Maher
Journal:  Oncoimmunology       Date:  2017-08-14       Impact factor: 8.110

5.  Production and Purification of Baculovirus for Gene Therapy Application.

Authors:  Md Nasimuzzaman; Johannes C M van der Loo; Punam Malik
Journal:  J Vis Exp       Date:  2018-04-09       Impact factor: 1.355

Review 6.  Targeting heparin and heparan sulfate protein interactions.

Authors:  Ryan J Weiss; Jeffrey D Esko; Yitzhak Tor
Journal:  Org Biomol Chem       Date:  2017-06-27       Impact factor: 3.876

7.  Heparan sulfate is an attachment factor for foamy virus entry.

Authors:  Kathrin Plochmann; Anne Horn; Eva Gschmack; Nicole Armbruster; Jennifer Krieg; Tatiana Wiktorowicz; Conrad Weber; Kristin Stirnnagel; Dirk Lindemann; Axel Rethwilm; Carsten Scheller
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

8.  Efficient transient genetic manipulation in vitro and in vivo by prototype foamy virus-mediated nonviral RNA transfer.

Authors:  Martin V Hamann; Nicole Stanke; Erik Müllers; Kristin Stirnnagel; Sylvia Hütter; Benedetta Artegiani; Sara Bragado Alonso; Federico Calegari; Dirk Lindemann
Journal:  Mol Ther       Date:  2014-05-12       Impact factor: 11.454

9.  Cocirculation of Two env Molecular Variants, of Possible Recombinant Origin, in Gorilla and Chimpanzee Simian Foamy Virus Strains from Central Africa.

Authors:  Léa Richard; Réjane Rua; Edouard Betsem; Augustin Mouinga-Ondémé; Mirdad Kazanji; Eric Leroy; Richard Njouom; Florence Buseyne; Philippe V Afonso; Antoine Gessain
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

10.  Intravenous injection of a foamy virus vector to correct canine SCID-X1.

Authors:  Christopher R Burtner; Brian C Beard; Douglas R Kennedy; Martin E Wohlfahrt; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Troy R Torgerson; David J Rawlings; Peter J Felsburg; Hans-Peter Kiem
Journal:  Blood       Date:  2014-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.